A coronavirus vaccine developed by the University of Oxford appears safe and triggers an immune response. A technique similar to the Oxford one, developed in China, also seems promising. In total there are 23 vaccines in clinical trials around the world and another 140 in early stage development.
The Nigeria Centre for Disease Control (NCDC) has expressed excitement over the development, saying the third phase of the trial vaccines will determine their efficacies against the disease.
The vaccines, developed by the University of Oxford and AstraZeneca have shown signs of inducing an immune response in patients involved in its trials.
According to The Lancet, The trial results found that the vaccines generated two ‘strong’ immune responses: the production of both antibodies and T cells, which find and attack virus cells.
The Director, Jenner Institute, Oxford University, Adrian Hill, said: “We are getting both sides of the immune system stimulated and that is fairly unusual for vaccines.”
An infectious disease expert at Vanderbilt University Medical Center in Nashville, Dr. William Schaffner, said: “It is good news. It is another step forward on the long road to having a COVID-19 vaccine.” Schaffner was however not involved in the vaccine research.
Dozens of teams across the world are working on other potential COVID-19 vaccines.
Moderna, a Cambridge, Massachusetts-based biotech company, published its PHASE 1 trial results of its vaccine last week, and announced plans to begin its final phase of human testing at the end of July. In the phase 1 trial, researchers reported that all 45 volunteers developed antibodies to fighting the coronavirus.
Both the Moderna and Pfizer COVID-19 vaccines in development also suggested immune responses for antibodies and T cells, though Moderna’s T cell response was weaker.